Subtype
Urothelial Carcinoma
CI-CAN-00004188Explore in graph →
236 active trials5 approved drugs8 evidence items
- NCIt
- C4030
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004188Explore in graph →
Clinical trials
623 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (99)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03093922 | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer | completed | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT01261728 | Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma | completed | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 |
| clinicaltrials |
| NCT03502785 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | completed | Phase 1 / Phase 2 | 35 | Inovio PharmaceuticalsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03782207 | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice(IMreal) | completed | — | 2,756 | Hoffmann-La RocheINDUSTRY | 30 | Aug 13, 2026 | clinicaltrials |
| NCT06412848 | JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study | completed | — | 360 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04773951 | A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors | completed | Phase 1 | 47 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 3 | 506 | National Cancer Institute (NCI)NIH | 2 | Jun 24, 2026 | clinicaltrials |
| NCT04018053 | 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy | completed | Early Phase 1 | 16 | Brigham and Women's HospitalOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03677544 | Predictive Factorsfor Final Pathologic Ureteral Sections(CYSTECTOMEN) | completed | — | 748 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04944550 | New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract.(CICLOP) | completed | — | 20 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07386847 | A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer | completed | — | 1 | PfizerINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT04146064 | Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response | completed | — | 190 | University Health Network, TorontoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04943380 | Efficacy and Utility of Cxbladder Tests in Hematuria Patients(DRIVE) | completed | — | 682 | Pacific Edge LimitedINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04822350 | A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA(AVENANCE) | completed | — | 596 | PfizerINDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05226117 | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | completed | Phase 2 | 44 | IRCCS San RaffaeleOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT01616875 | Bristol Bladder Trial | completed | Phase 2 | 28 | University Hospitals Bristol and Weston NHS Foundation TrustOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT02989064 | MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | completed | Phase 1 | 10 | AdaptimmuneINDUSTRY | 3 | Feb 4, 2026 | clinicaltrials |
| NCT04701918 | Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma | completed | Phase 2 | 9 | Massachusetts General HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05375903 | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 1 | 51 | UroGen Pharma Ltd.INDUSTRY | 3 | Jan 14, 2026 | clinicaltrials |
| NCT04553939 | Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer | completed | Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04566029 | Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas(AMI) | completed | — | 40 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT03575013 | A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer | completed | Phase 1 | 21 | Yousef ZakhariaOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT03039413 | Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | completed | Phase 1 | 146 | MacroGenicsINDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | completed | Phase 1 | 60 | Xencor, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT04570410 | Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma | completed | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05524545 | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) | completed | Phase 1 | 36 | ALX Oncology Inc.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05902494 | HER2 and LA/mUC: A Multi-country Chart Review Cohort Study | completed | — | 389 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 4 | Jul 20, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | completed | Phase 1 | 20 | Celldex TherapeuticsINDUSTRY | 1 | Jun 15, 2025 | clinicaltrials |
| NCT03988309 | STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA | completed | N/A | 554 | Pacific Edge LimitedINDUSTRY | 2 | May 31, 2025 | clinicaltrials |
| NCT02844816 | Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer | completed | Phase 2 | 172 | National Cancer Institute (NCI)NIH | 2 | May 22, 2025 | clinicaltrials |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 40 | Aprea TherapeuticsINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT01437488 | Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy | completed | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT05945108 | Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER | completed | — | 400 | AstraZenecaINDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03473756 | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma(FORT-2) | completed | Phase 1 | 37 | BayerINDUSTRY | 8 | Apr 9, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT05431777 | A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread | completed | — | 79 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Apr 1, 2025 | clinicaltrials |
| NCT02365766 | Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects | completed | Phase 1 / Phase 2 | 83 | Jason R. BrownOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT03871036 | Improve Checkpoint-blockade Response in Advanced Urothelial Cancer(ICRA) | completed | Phase 1 / Phase 2 | 53 | The Netherlands Cancer InstituteOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03387761 | Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy(NABUCCO) | completed | Phase 1 | 54 | The Netherlands Cancer InstituteOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04871594 | Pre-operative Immunotherapy in Stage II-III Urothelial Cancer(TURANDOT) | completed | Phase 1 | 15 | The Netherlands Cancer InstituteOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT02567409 | Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 44 | PureTechINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials